# Bristol-Myers Squibb CDR (CAD Hedged) (BMY.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: null. Price C$22.96, market value C$178.7 billion.

## Valuation
- **P/E (trailing): 13.8×**. Bristol-Myers Squibb CDR (CAD Hedged) trades at 13.8× trailing earnings.
- **Price / sales: 3.6×**. Each dollar of revenue is priced at 3.6×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 13.6×**. Enterprise value is 13.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.2%**. Free cash flow equals 5.2% of the market value. Above 5% is generally attractive.
- **Earnings yield: 7.2%**. The inverse of the P/E: 7.2% of the price is earned each year.

## Profitability
- **Gross margin: 69.2%**. Bristol-Myers Squibb CDR (CAD Hedged) keeps 69.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 29.2%**. 29.2% of revenue is left after running the business, an exceptional level.
- **Net margin: 14.6%**. 14.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 38.2%**. 38.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 21.7%**. Return on all capital, debt included, is 21.7%: comfortably above what that capital costs.
- **Return on assets: 10.3%**. Each dollar of assets produces 10.3% of profit.

## Growth
- **Revenue growth (1 yr): -0.2%** (3-yr 1.4%/yr). Revenue fell 0.2% over the last year.
- **EPS growth (1 yr): 178.5%** (3-yr 5.5%/yr). Earnings per share rose 178.5%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 2.4%/yr**. Free cash flow has compounded at 2.4% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 2.55**. Debt is 2.55 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.3×**. It would take 2.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 8.8×**. Operating profit covers interest 8.8× over, a safe margin.
- **Current ratio: 1.26** (quick 1.14). Current assets cover the next year's liabilities 1.26 times.
- **Altman Z-score: 2.92**. A Z-score of 2.92 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Bristol-Myers Squibb CDR (CAD Hedged) does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -2.0%** (2.7% above the low). Trading within 5% of its 52-week high.

Live score and charts: https://foliofundamentals.com/analyzer?s=BMY.TO · Page: https://foliofundamentals.com/stocks/bmy.to

Not investment advice.